NAV

Itolizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Itolizumab
DrugBank Accession Number
DB16207
Background

Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

Type
Biotech
Groups
Investigational
Synonyms
  • Itolizumab
External IDs
  • BMAB-600
  • EQ001
  • T1H
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Itolizumab binds to CD6 which modulates T-lymphocyte activation and proliferation. It is an efficacious immunomodulatory compound investigated for treating psoriasis. Currently, the full mechanisms of action are still unclear.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
XQQ2RHV14N
CAS number
1116433-11-4

References

General References
  1. Menon R, David BG: Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2015 Apr 17;8:215-22. doi: 10.2147/CCID.S47784. eCollection 2015. [Article]
  2. Dogra S, Uprety S, Suresh SH: Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. Expert Opin Biol Ther. 2017 Mar;17(3):395-402. doi: 10.1080/14712598.2017.1279601. Epub 2017 Jan 25. [Article]
  3. Pai G, Pai AH: Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis. Case Rep Dermatol. 2017 Aug 23;9(2):141-145. doi: 10.1159/000475519. eCollection 2017 May-Aug. [Article]
Wikipedia
Itolizumab

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentAcute Graft-Versus-Host Disease (GVHD) / Graft-versus-host Disease (GVHD)1
3WithdrawnTreatmentCoronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus1
2CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) / Cytokine Release Syndrome1
1Active Not RecruitingTreatmentLupus Erythematosus / Lupus Nephritis1
1CompletedTreatmentAsthma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 15, 2020 18:15 / Updated at February 21, 2021 18:55